Raymond James Financial
RNAM

Raymond James Financial’s Avidity Biosciences RNAM Stock Holding History

Raymond James Financial’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-57,078
Closed -$4.12M – 5426
2025
Q4 		$4.12M Sell
57,078
-109,533
-66% -$7.08M ﹤0.01% 2668
2025
Q3 		$7.26M Buy
166,611
+15,376
+10% +$622K ﹤0.01% 2181
2025
Q2 		$4.3M Sell
151,235
-8,029
-5% -$239K ﹤0.01% 2476
2025
Q1 		$4.7M Sell
159,264
-39,643
-20% -$1.23M ﹤0.01% 2374
2024
Q4 		$5.78M Buy
+198,907
New +$8.31M ﹤0.01% 2229

Other funds holding RNAM

CC
Corsicana & Co Corsicana, Texas $158M AUM

Raymond James Financial's RNAM Position: Q1 2026 in Review

Raymond James Financial sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 57,078 shares — an estimated $4.12M sold.

Raymond James Financial first reported a position in RNAM in Q4 2024 and held it in 5 quarters. The position peaked at $7.26M in Q3 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • Raymond James Financial reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • Raymond James Financial sold 57,078 Avidity Biosciences shares in Q1 2026, an estimated $4.12M.
  • Raymond James Financial first reported a position in Avidity Biosciences in Q4 2024 and held it in 5 quarters.
  • Raymond James Financial's Avidity Biosciences position peaked at $7.26M in Q3 2025.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.